Paper36978917
Auranofin Synergizes with the PARP Inhibitor Olaparib to Induce ROS-Mediated Cell Death in Mutant p53 Cancers.
Freire Boullosa L and 11 others. Antioxidants (Basel), 2023. Cited by 20 papers, by iCite.
Cite this record
ConductScience Library. Auranofin Synergizes with the PARP Inhibitor Olaparib to Induce ROS-Mediated Cell Death in Mutant p53 Cancers. Papers, record 36978917. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36978917
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Auranofin Synergizes with the PARP Inhibitor Olaparib to Induce ROS-Mediated Cell Death in Mutant p53 Cancers.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 11E7719 N | Research Foundation - Flanders | PubMed | ||
| 1520819 N | Research Foundation - Flanders | PubMed | ||
| NCR 19-20366 | AstraZeneca (France) | PubMed |
Source PubMed
References74
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 29416738 | PARP-1 inhibitors sensitize HNSCC cells to APR-246 by inactivation of thioredoxin reductase 1 (TrxR1) and promotion of ROS accumulation. | Oncotarget | 2018 | https://conductscience.org/library/papers/29416738 | PubMed |
| 2 | 30645701 | Pancreatic cancer microenvironment: a current dilemma. | Clin Transl Med | 2019 | https://conductscience.org/library/papers/30645701 | PubMed |
| 3 | 28452926 | KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 Mutations in Pancreatic Cancer. | Cancers (Basel) | 2017 | https://conductscience.org/library/papers/28452926 | PubMed |
| 4 | 26776881 | Auranofin-loaded nanoparticles as a new therapeutic tool to fight streptococcal infections. | Sci Rep | 2016 | https://conductscience.org/library/papers/26776881 | PubMed |
| 5 | 29577855 | Nanoparticles in Cancer Treatment: Opportunities and Obstacles. | Curr Drug Targets | 2018 | https://conductscience.org/library/papers/29577855 | PubMed |
| 6 | 24157875 | APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase. | Cell Death Dis | 2013 | https://conductscience.org/library/papers/24157875 | PubMed |
| 7 | 21779443 | The genomics of lung adenocarcinoma: opportunities for targeted therapies. | Genes Cancer | 2010 | https://conductscience.org/library/papers/21779443 | PubMed |
| 8 | 26431378 | Auranofin induces apoptosis by ROS-mediated ER stress and mitochondrial dysfunction and displayed synergistic lethality with piperlongumine in gastric cancer. | Oncotarget | 2015 | https://conductscience.org/library/papers/26431378 | PubMed |
| 9 | 33575569 | Omics Playground: a comprehensive self-service platform for visualization, analytics and exploration of Big Omics Data. | NAR Genom Bioinform | 2020 | https://conductscience.org/library/papers/33575569 | PubMed |
| 10 | 35580060 | SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples. | Nucleic Acids Res | 2022 | https://conductscience.org/library/papers/35580060 | PubMed |
| 11 | 27582430 | Excessive Reactive Oxygen Species and Exotic DNA Lesions as an Exploitable Liability. | Biochemistry | 2016 | https://conductscience.org/library/papers/27582430 | PubMed |
| 12 | 32782491 | PARP inhibition and immune modulation: scientific rationale and perspectives for the treatment of gynecologic cancers. | Ther Adv Med Oncol | 2020 | https://conductscience.org/library/papers/32782491 | PubMed |
| 13 | 34426760 | Reactive Oxygen Species (ROS) Regulates Different Types of Cell Death by Acting as a Rheostat. | Oxid Med Cell Longev | 2021 | https://conductscience.org/library/papers/34426760 | PubMed |
| 14 | 22711857 | BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. | J Clin Oncol | 2012 | https://conductscience.org/library/papers/22711857 | PubMed |
| 15 | 33088256 | Which concentrations are optimal for in vitro testing? | EXCLI J | 2020 | https://conductscience.org/library/papers/33088256 | PubMed |
| 16 | 33837299 | Exploiting the reactive oxygen species imbalance in high-risk paediatric acute lymphoblastic leukaemia through auranofin. | Br J Cancer | 2021 | https://conductscience.org/library/papers/33837299 | PubMed |
| 17 | 24287781 | Modulation of oxidative stress as an anticancer strategy. | Nat Rev Drug Discov | 2013 | https://conductscience.org/library/papers/24287781 | PubMed |
| 18 | 22899716 | Mutant p53R273H attenuates the expression of phase 2 detoxifying enzymes and promotes the survival of cells with high levels of reactive oxygen species. | J Cell Sci | 2012 | https://conductscience.org/library/papers/22899716 | PubMed |
| 19 | 26975633 | APR-246 (PRIMA-1(MET)) strongly synergizes with AZD2281 (olaparib) induced PARP inhibition to induce apoptosis in non-small cell lung cancer cell lines. | Cancer Lett | 2016 | https://conductscience.org/library/papers/26975633 | PubMed |
| 20 | 35201489 | The gold complex auranofin: new perspectives for cancer therapy. | Discov Oncol | 2021 | https://conductscience.org/library/papers/35201489 | PubMed |
Cited by11
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 20 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42529971 | TrxR Inhibition and Nrf2-FOXO3 Modulation by Repurposed Drugs: A Redox Strategy to Reverse Cancer Multidrug Resistance. | Drug Dev Res | 2026 | https://conductscience.org/library/papers/42529971 | PubMed |
| 41683548 | Auranofin Combination Therapy: A New Frontier in Cancer Treatment. | Molecules | 2026 | https://conductscience.org/library/papers/41683548 | PubMed |
| 41458252 | Spray Drying for Pharmaceutical Raw Materials: A Systematic Review on Enhancing Bioavailability and Stability. | Drug Des Devel Ther | 2025 | https://conductscience.org/library/papers/41458252 | PubMed |
| 41392982 | Auranofin attenuates TOPBP1-mediated ATR replication stress response and improves chemotherapeutic response in breast tumor models. | J Clin Invest | 2025 | https://conductscience.org/library/papers/41392982 | PubMed |
| 39288141 | Repurposing auranofin and meclofenamic acid as energy-metabolism inhibitors and anti-cancer drugs. | PLoS One | 2024 | https://conductscience.org/library/papers/39288141 | PubMed |
| 39187531 | NLRP4 renders pancreatic cancer resistant to olaparib through promotion of the DNA damage response and ROS-induced autophagy. | Cell Death Dis | 2024 | https://conductscience.org/library/papers/39187531 | PubMed |
| 39065655 | Investigation of Stabilized Amorphous Solid Dispersions to Improve Oral Olaparib Absorption. | Pharmaceutics | 2024 | https://conductscience.org/library/papers/39065655 | PubMed |
| 38590196 | [Role of Ferroptosis in Non-small Cell Lung Cancer and Progress of Traditional Chinese Medicine Intervention]. | Zhongguo Fei Ai Za Zhi | 2024 | https://conductscience.org/library/papers/38590196 | PubMed |
| 38515565 | Ferroptosis in lung cancer: dual role, multi-level regulation, and new therapeutic strategies. | Front Oncol | 2024 | https://conductscience.org/library/papers/38515565 | PubMed |
| 38515178 | Auranofin repurposing for lung and pancreatic cancer: low CA12 expression as a marker of sensitivity in patient-derived organoids, with potentiated efficacy by AKT inhibition. | J Exp Clin Cancer Res | 2024 | https://conductscience.org/library/papers/38515178 | PubMed |
| 38232457 | Thioredoxin (Trx): A redox target and modulator of cellular senescence and aging-related diseases. | Redox Biol | 2024 | https://conductscience.org/library/papers/38232457 | PubMed |
Genes12
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36978917
GET https://conductscience.org/api/papers/v1/36978917/references?page=2